본문 바로가기

카테고리 없음

HR Positive/ HER2 Negative Breast Cancer Market

HR Positive/ HER2 Negative Breast Cancer Market

HR-positive/HER2-negative breast cancer is the most common form of breast cancer and also accounts for a higher percentage of all breast cancers. HR-positive cancer is usually treated with hormone therapies or a combination of hormone therapies with targeted therapy to help stop tumor growth. A number of classes of anti estrogenic agents available for patients with early, advanced, or metastatic breast cancer includes selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs), and a selective estrogen receptor degrader.

 

 

DelveInsight’s “HR Positive/ HER2 Negative Breast Cancer Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer, historical and forecasted epidemiology as well as the Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

HR Positive/ HER2 Negative Breast Cancer Market Insights

  • Among the 7MM, the US accounts for the 80.51% USD of the overall market size of ER-positive/HER2-negative Breast Cancer in 2017.

  • In Japan, a higher number of cases were observed for postmenopausal Breast cancer, i.e., 71,280 cases post-menopause category, while only 17,820 patients were observed for premenopause in 2017.

  • The most incident cases of ER+/HER– breast cancer were recorded in the United States.

  • The lowest incident population of ER+/HER– breast cancer was recorded in Japan.

  • Among the EU5 countries, Germany accounts for the highest market size for ER-positive/HER2-negative Breast Cancer followed by France, Italy, the UK, and Spain.

HR Positive/ HER2 Negative Breast Cancer Market

The Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology. 

 

HR Positive/ HER2 Negative Breast Cancer Epidemiology

Hormone receptors are proteins that receive hormone signals and initiate the cancer cells to grow. If breast cancer cells get signals from the hormone estrogen that could promote tumor growth, it is known as estrogen receptor-positive (ER+) breast cancer. Breast cancer that is ER-positive or PR-positive falls under the category of hormone receptor-positive (HR+) breast cancer. Breast cancer cells may have one, both, or none of these receptors.

 The Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer epidemiology section covers insights about historical and current Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

 

HR Positive/ HER2 Negative Breast Cancer Drugs Uptake and Key Market Players

The Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer market or expected to get launched in the market during the study period. The analysis covers Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer market uptake by drugs; patient uptake by therapies; and sales of each drug.    

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

 

Some of the key players in HR Positive/ HER2 Negative Breast Cancer market include

  • Pfizer

  • Novartis

  • AstraZeneca Pharmaceuticals

  • Eli Lilly

  • Novartis Pharmaceuticals

  • Pharmacia and Upjohn Company

  • Odonate Therapeutics

  • Radius Pharmaceuticals

  • Immunomedics

  • Roche

  • Syndax Pharmaceuticals

  • Takeda Pharmaceuticals

  • GlaxoSmithKline

  • Merck Sharp and Dohme Corp.

And many others.

 

For more details visit:

https://www.delveinsight.com/report-store/hr-positive-her2-negative-breast-cancer-market-insights